Clinical trials: active, sponsored by H. Lundbeck A/S
Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol.
- Trial name
- BalanCeD (NCT06471829)
- Testing
- Lu AG13909
- Where
- 27 sites in United States, France and 7 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Chronic Migraine in Children
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
- Trial name
- PROSPECT-2 (NCT04965675)
- Testing
- Eptinezumab
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 285 people
- Sponsor
- H. Lundbeck A/S
Episodic Migraine
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
- Trial name
- PROSPECT-1 (NCT05897320)
- Testing
- Eptinezumab
- Where
- 60 sites in United States, Argentina and 9 more
- Volunteers
- 315 people
- Sponsor
- H. Lundbeck A/S
Healthy Participants
A Trial of Lu AH69593 in Healthy Participants
This trial will evaluate the effects of itraconazole (Part A) and, carbamazepine (Part B) on Lu AH69593, and the effect of Lu AH69593 on midazolam (Part C) in adult healthy participants.
- Trial name
- NCT07775261
- Testing
- Lu AH69593, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
- Trial name
- MASCOT (NCT06706622)
- Testing
- Amlenetug
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 401 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
- Trial name
- REJOIN (NCT05164172)
- Testing
- Eptinezumab
- Where
- 64 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Adrenal Hyperplasia, Congenital
An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia
The main goal of the trial is to study the long-term safety, how well people can handle the treatment, and how asedebart acts in the body and affects the body when used to treat classic congenital adrenal hyperplasia (CAH).
- Trial name
- NCT07859293
- Testing
- Asedebart
- Volunteers
- 45 people
- Sponsor
- H. Lundbeck A/S
Thyroid Eye Disease
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
- Trial name
- NCT06557850
- Testing
- Lu AG22515
- Where
- 6 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 20 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment.
- Trial name
- DARE2 (NCT07514858)
- Testing
- Lu AF28996
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- H. Lundbeck A/S
Narcolepsy
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy
The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.
- Trial name
- NCT07613710
- Testing
- Lu AH69593
- Where
- 2 sites in Finland
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Parkinson Disease
A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
- Trial name
- NCT07513441
- Testing
- Lu AF28996
- Where
- 4 sites in China
- Volunteers
- 10 people
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
A Study of Lu AF82422 in Participants With Multiple System Atrophy
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Trial name
- AMULET (NCT05104476)
- Testing
- Lu AF82422
- Where
- 19 sites in United States, Japan
- Volunteers
- 64 people
- Sponsor
- H. Lundbeck A/S
Congenital Adrenal Hyperplasia
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH.
- Trial name
- NCT05669950
- Testing
- Lu AG13909
- Where
- 17 sites in United States, Denmark and 7 more
- Volunteers
- 42 people
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
Observational Study in Multiple System Atrophy
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]).
- Trial name
- TALISMAN (NCT05453058)
- Testing
- plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- H. Lundbeck A/S